Thiotepa + Carmustine + Busulfan Combination

The combination of thiotepa, carmustine (BCNU), and busulfan is mentioned as a conditioning regimen used in high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for primary central nervous system lymphoma (PCNSL). It is noted for excellent CNS bioavailability. The provided information details the use, efficacy, variations (Thiotepa/Carmustine and Thiotepa/Busulfan/Cyclophosphamide), dosing, administration, safety, and toxicity primarily of these related regimens, as the text does not provide specific details for the explicit thiotepa + carmustine + busulfan combination. These conditioning regimens are primarily used for refractory or recurrent PCNSL, showing significant efficacy in chemosensitive patients up to 65 years of age. Thiotepa-based regimens, including combinations with carmustine or busulfan/cyclophosphamide, have shown favorable outcomes. A comparative study in older patients (≥65) found BCNU/Thio had lower non-relapse mortality and improved survival compared to TBC.